WO2014016548A3 - Composition pharmaceutique - Google Patents
Composition pharmaceutique Download PDFInfo
- Publication number
- WO2014016548A3 WO2014016548A3 PCT/GB2013/000328 GB2013000328W WO2014016548A3 WO 2014016548 A3 WO2014016548 A3 WO 2014016548A3 GB 2013000328 W GB2013000328 W GB 2013000328W WO 2014016548 A3 WO2014016548 A3 WO 2014016548A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- olodaterol
- further active
- pharmaceutical composition
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention porte sur des compositions pharmaceutiques pour inhalation qui comprennent un ou plusieurs bronchodilatateurs et un corticostéroïde inhalé. Plus particulièrement, la présente invention porte sur des compositions pharmaceutiques comprenant de l'olodaterol, un corticostéroïde inhalé et/ou un agent anticholinergique. La présente invention porte également sur un procédé pour la préparation de la composition pharmaceutique et sur son utilisation dans le traitement et/ou la prévention d'une maladie respiratoire, inflammatoire ou obstructive des voies aériennes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2161MU2012 | 2012-07-27 | ||
IN2161/MUM/2012 | 2012-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014016548A2 WO2014016548A2 (fr) | 2014-01-30 |
WO2014016548A3 true WO2014016548A3 (fr) | 2014-03-20 |
Family
ID=48949176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2013/000328 WO2014016548A2 (fr) | 2012-07-27 | 2013-07-29 | Composition pharmaceutique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014016548A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2952701C (fr) * | 2014-06-18 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Antagonistes muscariniques et leurs combinaisons pour le traitement de maladie des voies respiratoires chez des chevaux |
CN104546861A (zh) * | 2015-01-13 | 2015-04-29 | 段希福 | 一种包含奥达特罗和环索奈德的药物组合物及其用途 |
GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
BR122020022602B1 (pt) | 2015-12-04 | 2024-03-05 | Mexichem Fluor S.A. De C.V. | Composição farmacêutica |
ES2956521T3 (es) * | 2016-09-19 | 2023-12-22 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende bromuro de tiotropio |
US20190290633A1 (en) * | 2017-10-27 | 2019-09-26 | Nephron Pharmaceuticals Corporation | Tiotropium Inhalation Solution for Nebulization |
WO2019142214A1 (fr) * | 2018-01-19 | 2019-07-25 | Cipla Limited | Composition pharmaceutique comprenant du tiotropium destinée à être inhalée |
CN110876724A (zh) * | 2018-09-06 | 2020-03-13 | 天津金耀集团有限公司 | 依地酸盐恰当改变噻托溴铵奥达特罗喷雾剂表面张力的应用 |
CN110876722A (zh) * | 2018-09-06 | 2020-03-13 | 天津金耀集团有限公司 | 一种含有表面活性剂的噻托溴铵奥达特罗喷雾剂 |
WO2021211858A1 (fr) * | 2020-04-16 | 2021-10-21 | Anovent Pharmaceutical (U.S.), Llc | Formulation inhalable d'une solution contenant du bromure de tiotropium et de l'olodatérol |
CN115835885A (zh) * | 2020-06-23 | 2023-03-21 | 广州谷森制药有限公司 | 包含奥达特罗和布地奈德的药物组合物的制备 |
CN114028364A (zh) * | 2021-11-26 | 2022-02-11 | 南京华盖制药有限公司 | 一种奥达特罗吸入溶液 |
CN117679423A (zh) * | 2022-09-05 | 2024-03-12 | 立生医药(苏州)有限公司 | 预防或治疗呼吸系统疾病的吸入用药物组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102349A1 (fr) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Combinaisons medicamenteuses contenant de la benzoxazine pour traiter des maladies des voies respiratoires |
WO2008020056A2 (fr) * | 2006-08-18 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulation aérosol pour l'inhalation de bêta-agonistes |
WO2008020057A1 (fr) * | 2006-08-18 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulation d'aérosol pour l'inhalation de bêta-agonistes |
WO2009059893A1 (fr) * | 2007-11-05 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Hydrate cristallin de bêta-mimétique et son utilisation en tant que médicament |
WO2011073231A1 (fr) * | 2009-12-18 | 2011-06-23 | Nycomed Gmbh | Dérivés de 3,4,4a,10b-tétrahydro-1h-thiopyrano-[4,3-c]isoquinoline |
WO2012110770A2 (fr) * | 2011-02-17 | 2012-08-23 | Cipla Limited | Composition pharmaceutique |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050239778A1 (en) | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
US20070088030A1 (en) | 2005-10-10 | 2007-04-19 | Barbara Niklaus-Humke | Aerosol formulations for the inhalation of beta-agonists |
TWI396541B (zh) | 2005-10-10 | 2013-05-21 | Boehringer Ingelheim Int | 用於治療呼吸疾病之新穎藥物組合 |
-
2013
- 2013-07-29 WO PCT/GB2013/000328 patent/WO2014016548A2/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102349A1 (fr) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Combinaisons medicamenteuses contenant de la benzoxazine pour traiter des maladies des voies respiratoires |
WO2008020056A2 (fr) * | 2006-08-18 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulation aérosol pour l'inhalation de bêta-agonistes |
WO2008020057A1 (fr) * | 2006-08-18 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulation d'aérosol pour l'inhalation de bêta-agonistes |
WO2009059893A1 (fr) * | 2007-11-05 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Hydrate cristallin de bêta-mimétique et son utilisation en tant que médicament |
WO2011073231A1 (fr) * | 2009-12-18 | 2011-06-23 | Nycomed Gmbh | Dérivés de 3,4,4a,10b-tétrahydro-1h-thiopyrano-[4,3-c]isoquinoline |
WO2012110770A2 (fr) * | 2011-02-17 | 2012-08-23 | Cipla Limited | Composition pharmaceutique |
Non-Patent Citations (1)
Title |
---|
M. CAZZOLA ET AL: "Pharmacology and Therapeutics of Bronchodilators", PHARMACOLOGICAL REVIEWS, vol. 64, no. 3, 18 May 2012 (2012-05-18), pages 450 - 504, XP055083801, DOI: 10.1124/pr.111.004580 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014016548A2 (fr) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014016548A3 (fr) | Composition pharmaceutique | |
WO2012110770A3 (fr) | Composition pharmaceutique | |
WO2012016889A3 (fr) | Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase | |
TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
WO2013021199A3 (fr) | Compositions pharmaceutiques | |
PH12017502087B1 (en) | Tiotropium inhalation solution for nebulization | |
WO2014064410A3 (fr) | Composition pharmaceutique | |
TR201000680A2 (tr) | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler | |
WO2013112959A8 (fr) | Composés antifibrotiques et leurs utilisations | |
WO2014018668A3 (fr) | Composés analogues de pirfénidone et de pyridone pour aérosol et leurs utilisations | |
WO2011152804A3 (fr) | Procédé pour formulations pulvérulentes sèches | |
WO2013036610A3 (fr) | Compositions comprenant le mg53 et procédés de traitement et de prévention de lésions au niveau des voies respiratoires | |
WO2014007770A3 (fr) | Compositions d'inhalation comprenant un corticostéroïde et du sorbitol | |
WO2014007772A3 (fr) | Compositions d'inhalation contenant du glucose anhydre | |
PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
WO2014007781A3 (fr) | Compositions d'inhalation | |
MX357556B (es) | Composiciones acuosas que comprenden arbekacina. | |
WO2011093818A3 (fr) | Compositions pharmaceutiques comprenant du salmétérol et du fluticasone | |
WO2011113000A8 (fr) | Compositions inédites contenant des esters et méthodes associées | |
UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
WO2013153349A3 (fr) | Composition pharmaceutique | |
WO2019098969A3 (fr) | Compositions de poudre sèche à inhaler | |
WO2011093812A3 (fr) | Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche | |
TN2013000015A1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
WO2011093810A3 (fr) | Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13747480 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13747480 Country of ref document: EP Kind code of ref document: A2 |